Revenue
2013
2014
2015
2018
2019
2020
2021
2022
2023
2024
2025
Zevra Therapeutics, Inc. (ZVRA)
Price$12.40Cached quote
Net income
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $106.5M | $23.6M | $27.5M | $10.2M | $28.6M | $13.3M | $12.8M | $0 | — | — | $0 | $0 | $0 |
| Gross profit | $90.0M | $16.2M | $24.5M | $9.9M | $26.6M | — | $2.8M | $0 | — | — | — | — | — |
| Gross margin | 84.52% | 68.59% | 89.28% | 97.82% | 92.81% | — | 22.11% | — | — | — | — | — | — |
| Research & development | $12.7M | $42.1M | $39.8M | $19.8M | $10.2M | $8.8M | $19.4M | $41.8M | $20.6M | $20.5M | $13.9M | $11.9M | $3.4M |
| Operating expenses | $152.9M | $103.2M | $77.1M | $52.7M | $20.9M | $18.9M | $33.2M | $55.9M | $33.4M | $37.5M | $22.8M | $16.4M | $4.7M |
| Operating income | −$62.9M | −$87.0M | −$49.6M | −$42.6M | $7.7M | −$5.6M | −$20.3M | −$55.9M | −$33.4M | −$37.5M | −$22.8M | −$16.4M | −$4.7M |
| Operating margin | −59.12% | −368.47% | −180.63% | −418.91% | 26.98% | −42.21% | −158.40% | — | — | — | — | — | — |
| EBITDA | −$58.9M | −$80.6M | −$48.6M | −$41.6M | $8.0M | −$5.3M | −$20.0M | −$55.6M | −$33.0M | −$37.3M | −$22.7M | −$16.4M | −$4.7M |
| EBITDA margin | −55.31% | −341.41% | −176.97% | −409.62% | 27.87% | −40.16% | −156.03% | — | — | — | — | — | — |
| Net income | $83.2M | −$105.5M | −$46.0M | −$26.8M | −$8.6M | −$12.8M | −$24.5M | −$56.5M | −$43.4M | −$16.5M | −$54.7M | −$24.5M | −$5.2M |
| Net profit margin | 78.17% | −446.85% | −167.69% | −263.48% | −29.86% | −96.03% | −191.00% | — | — | — | — | — | — |
| Basic EPSper basic share | $1.40 | -$2.28 | -$1.30 | -$0.78 | -$2.11 | -$3.21 | -$13.23 | -$50.40 | -$47.36 | -$18.08 | -$118.72 | -$164.32 | -$35.20 |
| Diluted EPSper diluted share | $1.35 | -$2.28 | -$1.30 | -$1.20 | -$2.11 | -$3.21 | -$13.23 | -$50.40 | -$47.36 | -$18.08 | -$118.72 | -$164.32 | -$35.20 |
Owners
Reported shareholders
8.61%of listed shares
BlackRock, Inc.5.11M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
BlackRock, Inc. | 8.61%5.11M shares |
FMR LLC | 8.28%4.92M shares |
Woodline Partners LP | 8.06%4.79M shares |
Nantahala Capital Management, LLC | 6.06%3.59M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.45%2.64M shares |
STATE STREET CORP | 2.83%1.68M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.60%1.54M shares |
D. E. Shaw & Co., Inc. | 2.20%1.31M shares |
Qube Research & Technologies Ltd | 2.09%1.24M shares |
MORGAN STANLEY | 2.03%1.2M shares |
Legal & General Group Plc | 2.02%1.2M shares |
DIMENSIONAL FUND ADVISORS LP | 1.62%958.84K shares |
ROYCE & ASSOCIATES LP | 1.49%882.66K shares |
683 Capital Management, LLC | 1.44%855K shares |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 1.31%775K shares |
Retirement Planning Co of New England, Inc. | 1.07%634.41K shares |
Jupiter Topco LLC | 1.03%613.4K shares |
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 1.01%597.16K shares |
GOLDMAN SACHS GROUP INC | 0.92%545.55K shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 0.91%541.11K shares |
Percentages use 59.34M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 22, 2026Form 4 · 10b5-1 | Thompson RahsaanChief Legal & Compliance | SellCommon Stock | 34.6K | $12.68 | $438.2K | 80.2K |
| May 11, 2026Form 4 · 10b5-1 | Thompson RahsaanChief Legal & Compliance | SellCommon Stock | 1.8K | $11.30 | $20.3K | 48.1K |
| Feb 9, 2026Form 4 · 10b5-1 | McFarlane Neil F.President and CEO | SellCommon Stock | 14.6K | $8.56 | $125.2K | 387.2K |
| Feb 3, 2026Form 4 · 10b5-1 | Schafer JoshuaCCO | SellCommon Stock | 10.5K | $9.19 | $96.5K | 62.3K |
| Feb 3, 2026Form 4 · 10b5-1 | Sangiovanni Timothy J.SVP, Finance & Corp Controller | SellCommon Stock | 3.0K | $9.18 | $27.5K | 29.6K |